SCHEDULE: Squadron Funds Divest All Traws Pharma Shares

Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have reported zero beneficial ownership of Traws Pharma, Inc. common stock.

Summary

• Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have filed an amendment to Schedule 13G, reporting a reduction in their beneficial ownership of Traws Pharma, Inc. common stock to 0 shares.
• This filing indicates that the reporting persons no longer hold any shares of Traws Pharma, Inc. common stock.
• The date of the event requiring this filing was June 30, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the complete divestment of shares, indicating a lack of confidence or strategic shift away from Traws Pharma, Inc.

Negatives

• Complete divestment of all shares in Traws Pharma, Inc. by Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank.
• Reporting 0% ownership of the class of securities.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that a complete divestment by a fund, as indicated in this Schedule 13G filing, often signals a lack of confidence in the company's future prospects or a strategic reallocation of capital. This could be interpreted negatively by the market.

Stakeholder Impact

• Shareholders may view this divestment as a negative signal, potentially impacting the stock price.
• The market may interpret this as a lack of confidence from significant investors.

Key Dates

Recommendation

The complete divestment of shares by Squadron Master Fund LP and associated entities suggests a strong negative outlook on Traws Pharma, Inc.'s future performance, warranting a sell recommendation.

Keywords

Traws Pharma, Squadron Master Fund, Squadron Capital Management, Schedule 13G, Beneficial Ownership, Divestment